REGENXBIO Inc.
REGENXBIO Inc. is a U.S.-based biotechnology company focused on adeno-associated virus (AAV) gene therapy. It develops and licenses its NAV Technology Platform and related gene therapy programs, while also earning royalties and collaboration revenue from partnered products and services.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLicenses of the NAV Technology Platform and related intellectual property to biotech and pharma partners.
Royalty income tied mainly to sales of partnered gene therapy products such as Zolgensma and Itvisma.
Development, manufacturing, and other service work performed under collaboration agreements.
Products
Reported · share of revenue- Zolgensma Royalties48.5 %
- Nippon Shinyaku Licenses42.8 %
- Nippon Shinyaku Services6.9 %
- Other Service Revenue1.4 %
- Itvisma Royalties0.4 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
REGENXBIO sells primarily to a small number of biotechnology and pharmaceutical collaboration partners rather than to end patients. Its revenue comes from licensees, royalty payers, and partners that use the NAV platform to develop and commercialize gene therapies. The company also supports collaborators with development and manufacturing services tied to specific programs.
Companies licensing NAV Technology Platform rights for internal R&D and therapeutic development.
Partners that market licensed products and generate royalty streams for REGENXBIO.
Partners paying for development, manufacturing, and service work under collaboration agreements.
Strategy
REGENXBIO’s strategy centers on advancing its NAV AAV platform, expanding partnered gene therapy programs, and converting intellectual property into recurring royalty and licensing revenue. The company also seeks to progress its own product candidates and manufacturing capabilities so it can participate in both partnered and proprietary value creation. This model aims to combine platform monetization with long-duration upside from clinical programs.
Licensing broadens the installed base of programs that can generate upfront, milestone, and royalty economics.
Internal programs provide potential long-term product revenue beyond platform royalties.
AAV manufacturing capability is critical for clinical supply, quality, and future commercialization.
Geography
REGENXBIO is headquartered in Rockville, Maryland, and operates as a U.S.-based company. Its revenue exposure is tied to global partner commercialization, especially royalties from products sold in multiple territories through licensees. The business is therefore geographically driven more by partner sales footprints and regulatory approvals than by direct end-market operations.
Risks
The business depends on a small number of partners and on the success of a limited set of gene therapy programs, so revenue can be volatile and concentrated. Clinical, regulatory, manufacturing, and intellectual property risks are central because the company’s value depends on proving safety, efficacy, and scalable AAV production. As a biotechnology company, it also faces funding and commercialization risk if product development or partner adoption slows.
- Clinical development failureImpact: HighLikelihood: High
Lead product candidates must prove safety and efficacy in trials before commercialization is possible.
Exposure - Regulatory approval riskImpact: HighLikelihood: High
Gene therapy endpoints and follow-up requirements can delay or prevent approval.
Exposure: All investigational gene therapy programs
- Customer concentrationImpact: HighLikelihood: Medium
Most revenue comes from a very small number of partners, so loss or delay from one partner can materially reduce revenue.
Exposure: Novartis Gene Therapies and Nippon Shinyaku
- Intellectual property riskImpact: HighLikelihood: Medium
The platform depends on patents and third-party license rights that can be challenged or limited.
Exposure: NAV Technology Platform and licensed IP
- Manufacturing and quality riskImpact: MediumLikelihood: Medium
AAV vector production must meet clinical and commercial supply requirements with consistent yield and purity.
Exposure: NAV platform manufacturing processes and assays
Accounting
Judgemental itemsLicense, royalty, and service arrangements require judgment on performance obligations, timing, and transaction price allocation.
Impact: Can shift revenue between periods and create volatility
Some license agreements include imputed interest that is recognized over time.
Impact: Affects reported interest income from licensing
The company has royalty purchase/loan arrangements that create interest expense and balance sheet obligations.
Impact: Influences leverage, cash flow, and earnings presentation
Patent portfolio and related assets support the platform and may require impairment or valuation judgments.
Impact: Could affect asset carrying values and expense recognition
Similar listed companies
Publicly listed companies with a comparable business focus.
MeiraGTx Holdings plc
MGTX · Biological Products, (No Diagnostic Substances)
MeiraGTx Holdings plc is a clinical-stage genetic medicines company developing adeno-associated virus (AAV) gene therapies for inherited retinal disease,…
Regen BioPharma Inc
RGBPP · Pharmaceutical Preparations
Regen BioPharma Inc is a U.S.-based biopharmaceutical development company organized in Nevada and operating through its wholly owned subsidiary KCL Therapeutics, Inc.
Rocket Pharmaceuticals, Inc
RCKT · Pharmaceutical Preparations
Rocket Pharmaceuticals is a U.S.-based late-stage biotechnology company focused on developing genetic therapies for rare inherited diseases.
Genprex, Inc.
GNPX · Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Last updated: 24/09/2026